[The lipid-reducing efficiency of a clofibrate-inositolnicotinate combination in comparison with clofibrate. The wrong use of statistical methods--presented on an example from clinical research].
作者信息
Haase W, Kluthe R, Schäfer B
出版信息
Med Welt. 1975 Nov 21;26(47):2157-9.
PMID:1105056
Abstract
摘要
相似文献
1
2
[Letter: Clofibrate and clofibrate-inositolnicotinate].[信件：氯贝丁酯与氯贝丁酯-肌醇烟酸酯]
Dtsch Med Wochenschr. 1976 Aug 13;101(33):1236.
3
[The effect of a lipid-reducing clofibrate-inositolnicotinate combination compared to clofibrate. A double-blind study].
Med Welt. 1975 Apr 4;26(14):655-63.
4
5
6
[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].[氯苯氧异丁酸镁与肌醇六烟酸酯组合的药代动力学]
Acta Med Austriaca. 1977;4(3):120-4.
7
[Action of etofibrate, clofibrate and nicotinic acid on the metabolism of lipids in normolipemic rats. Short term effects and method of action].
Arch Farmacol Toxicol. 1979 Apr;5(1):29-42.
8
9
[Letter: Clofibrate and clofibrate-inositolnicotinate].[信件：氯贝丁酯与氯贝丁酯-肌醇烟酸酯]
Dtsch Med Wochenschr. 1976 Jun 18;101(25):975.
10
[Hypolipemic agents].
Minerva Med. 1973 Apr 14;64(24):1267-75.
Zotero 插件